Three-dimensional fibroblast cultures stimulate improved ventricular performance in chronically ischemic canine hearts

Robert S Kellar, Stuart K. Williams, Gail K. Naughton, Gianine M. Figliozzi, Michael Siani-Rose

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The current study's purpose was to evaluate the safety and biological effect of a scaffold-based three-dimensional human dermal fibroblast culture (3DFC, also known as Anginera™) to treat chronically ischemic canine hearts. It was hypothesized that treatment with 3DFC would be safe and significantly improve ventricular performance and wall motion. In this study, chronic myocardial ischemia was induced in 40 animals through the surgical placement of an ameroid constrictor. Approximately 30 days after ameroid placement, animals were randomized into four test groups: (1) sham treatment, (2) one unit of acellular 3DFC, (3) one unit of viable 3DFC, and (4) three units of viable 3DFC. Animals were necropsied 30 or 90 days after treatment. Evaluation of the safety endpoint demonstrated the safety of 3DFC at all dosing levels and at both time points. Additionally, parameters of cardiac output, left ventricular ejection fraction, left ventricular end systolic volume index, and systolic wall thickening support the conclusions that 3DFC stimulates a positive biologic effect on ischemic canine hearts. Further, these data support the conclusion that treatment with viable 3DFC improves ventricular performance and ventricular wall motion in chronically ischemic canine hearts 30 days after treatment.

Original languageEnglish (US)
Pages (from-to)2177-2186
Number of pages10
JournalTissue Engineering - Part A
Volume17
Issue number17-18
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Fibroblasts
Cell culture
Canidae
Animals
Safety
Stroke Volume
Scaffolds (biology)
Therapeutics
Cardiac Output
Myocardial Ischemia
Placebos
Skin
ameroid

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomedical Engineering
  • Biomaterials
  • Medicine(all)

Cite this

Three-dimensional fibroblast cultures stimulate improved ventricular performance in chronically ischemic canine hearts. / Kellar, Robert S; Williams, Stuart K.; Naughton, Gail K.; Figliozzi, Gianine M.; Siani-Rose, Michael.

In: Tissue Engineering - Part A, Vol. 17, No. 17-18, 01.09.2011, p. 2177-2186.

Research output: Contribution to journalArticle

Kellar, Robert S ; Williams, Stuart K. ; Naughton, Gail K. ; Figliozzi, Gianine M. ; Siani-Rose, Michael. / Three-dimensional fibroblast cultures stimulate improved ventricular performance in chronically ischemic canine hearts. In: Tissue Engineering - Part A. 2011 ; Vol. 17, No. 17-18. pp. 2177-2186.
@article{95cddbce23be4784a4324ae77c202d03,
title = "Three-dimensional fibroblast cultures stimulate improved ventricular performance in chronically ischemic canine hearts",
abstract = "The current study's purpose was to evaluate the safety and biological effect of a scaffold-based three-dimensional human dermal fibroblast culture (3DFC, also known as Anginera™) to treat chronically ischemic canine hearts. It was hypothesized that treatment with 3DFC would be safe and significantly improve ventricular performance and wall motion. In this study, chronic myocardial ischemia was induced in 40 animals through the surgical placement of an ameroid constrictor. Approximately 30 days after ameroid placement, animals were randomized into four test groups: (1) sham treatment, (2) one unit of acellular 3DFC, (3) one unit of viable 3DFC, and (4) three units of viable 3DFC. Animals were necropsied 30 or 90 days after treatment. Evaluation of the safety endpoint demonstrated the safety of 3DFC at all dosing levels and at both time points. Additionally, parameters of cardiac output, left ventricular ejection fraction, left ventricular end systolic volume index, and systolic wall thickening support the conclusions that 3DFC stimulates a positive biologic effect on ischemic canine hearts. Further, these data support the conclusion that treatment with viable 3DFC improves ventricular performance and ventricular wall motion in chronically ischemic canine hearts 30 days after treatment.",
author = "Kellar, {Robert S} and Williams, {Stuart K.} and Naughton, {Gail K.} and Figliozzi, {Gianine M.} and Michael Siani-Rose",
year = "2011",
month = "9",
day = "1",
doi = "10.1089/ten.tea.2010.0680",
language = "English (US)",
volume = "17",
pages = "2177--2186",
journal = "Tissue Engineering - Part A.",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "17-18",

}

TY - JOUR

T1 - Three-dimensional fibroblast cultures stimulate improved ventricular performance in chronically ischemic canine hearts

AU - Kellar, Robert S

AU - Williams, Stuart K.

AU - Naughton, Gail K.

AU - Figliozzi, Gianine M.

AU - Siani-Rose, Michael

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The current study's purpose was to evaluate the safety and biological effect of a scaffold-based three-dimensional human dermal fibroblast culture (3DFC, also known as Anginera™) to treat chronically ischemic canine hearts. It was hypothesized that treatment with 3DFC would be safe and significantly improve ventricular performance and wall motion. In this study, chronic myocardial ischemia was induced in 40 animals through the surgical placement of an ameroid constrictor. Approximately 30 days after ameroid placement, animals were randomized into four test groups: (1) sham treatment, (2) one unit of acellular 3DFC, (3) one unit of viable 3DFC, and (4) three units of viable 3DFC. Animals were necropsied 30 or 90 days after treatment. Evaluation of the safety endpoint demonstrated the safety of 3DFC at all dosing levels and at both time points. Additionally, parameters of cardiac output, left ventricular ejection fraction, left ventricular end systolic volume index, and systolic wall thickening support the conclusions that 3DFC stimulates a positive biologic effect on ischemic canine hearts. Further, these data support the conclusion that treatment with viable 3DFC improves ventricular performance and ventricular wall motion in chronically ischemic canine hearts 30 days after treatment.

AB - The current study's purpose was to evaluate the safety and biological effect of a scaffold-based three-dimensional human dermal fibroblast culture (3DFC, also known as Anginera™) to treat chronically ischemic canine hearts. It was hypothesized that treatment with 3DFC would be safe and significantly improve ventricular performance and wall motion. In this study, chronic myocardial ischemia was induced in 40 animals through the surgical placement of an ameroid constrictor. Approximately 30 days after ameroid placement, animals were randomized into four test groups: (1) sham treatment, (2) one unit of acellular 3DFC, (3) one unit of viable 3DFC, and (4) three units of viable 3DFC. Animals were necropsied 30 or 90 days after treatment. Evaluation of the safety endpoint demonstrated the safety of 3DFC at all dosing levels and at both time points. Additionally, parameters of cardiac output, left ventricular ejection fraction, left ventricular end systolic volume index, and systolic wall thickening support the conclusions that 3DFC stimulates a positive biologic effect on ischemic canine hearts. Further, these data support the conclusion that treatment with viable 3DFC improves ventricular performance and ventricular wall motion in chronically ischemic canine hearts 30 days after treatment.

UR - http://www.scopus.com/inward/record.url?scp=80053149603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053149603&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2010.0680

DO - 10.1089/ten.tea.2010.0680

M3 - Article

VL - 17

SP - 2177

EP - 2186

JO - Tissue Engineering - Part A.

JF - Tissue Engineering - Part A.

SN - 1937-3341

IS - 17-18

ER -